Biomedical Engineering Reference
In-Depth Information
33. Nattel S, Yue L, Wang Z (1999) Cardiac ultrarapid delayed rectifiers: a novel potassium
current family of functional similarity and molecular diversity. Cell Physiol Biochem
9:217-226
34. Nygren A, Fiset C, Firek L et al (1998) Mathematical model of an adult human atrial cell: the
role of K+ currents in repolarization. Circ Res 82:63-81
35. Courtemanche M, Ramirez RJ, Nattel S (1999) Ionic targets for drug therapy and atrial
fibrillation-induced electrical remodeling: insights from a mathematical model. Cardiovasc
Res 42:477-489
36. Brendel J, Peukert S (2002) Blockers of the Kv1.5 channel for the treatment of atrial
arrhythmias. Expert Opin Ther Pat 12:1589-1598
37. Brendel J, Peukert S (2003) Blockers of the Kv1.5 channel for the treatment of atrial
arrhythmias. Curr Med Chem Cardiovasc Hematol Agents 1:273-287
38. Yang Q, Du L, Wang X et al (2007) Strategies for atrial fibrillation therapy: focusing on I
Kur
potassium channel. Expert Opin Ther Pat 17:1443-1456
39. Jackson CM, Blass B, Coburn K et al (2007) Evolution of thiazolidine-based blockers of
human Kv1.5 for the treatment of atrial arrhythmias. Bioorg Med Chem Lett 17:282-284
40. Blass BE, Coburn K, Lee W et al (2006) Synthesis and evaluation of (2-phenethyl-2H-
1,2,3-triazol-4-yl)(phenyl)methanones as Kv1.5 channel blockers for the treatment of atrial
fibrillation. Bioorg Med Chem Lett 16:4629-4632
41. Wu S, Fluxe A, Sheffer J et al (2006) Discovery and in vitro/in vivo studies of tetrazole
derivatives as Kv1.5 blockers. Bioorg Med Chem Lett 16:6213-6218
42. Blass BE, Fensome A, Trybulski E et al (2009) Selective Kv1.5 blockers: development of (R)-1-
(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxypheny l)-2-imidazolidinone
(KVI-020/WYE-160020) as a potential
treatment
for atrial arrhythmia. J Med Chem
52:6531-6534
43. Janusz JM, Hodson SJ, Bosch GK et al (2007) Imidazolidinone derivatives as Kv1.5
potassium channel inhibitors and their preparation, pharmaceutical compositions and use
in the treatment of cardiac arrhythmia, WO 2007149874, Wyeth, USA, p 155
44. Blass BE, Janusz JM, Ridgeway JM et al (2009) Preparation of 4-imidazolidinones
as Kv1.5 potassium channel inhibitors, WO 2009079630, Wyeth, John, and Brother Ltd.,
USA, p 51
45. Blass BE, Janusz JM, Wu S et al (2009) Preparation of 4-imidazolidinones as kv1.5
potassium channel inhibitors, WO 2009079624, Wyeth, John, and Brother Ltd., USA, p 208
46. Wu S, Fluxe A, Janusz JM et al (2006) Discovery and synthesis of tetrahydroindolone
derived semicarbazones as selective Kv1.5 blockers. Bioorg Med Chem Lett 16:5859-5863
47. Fluxe A, Wu S, Sheffer JB et al (2006) Discovery and synthesis of tetrahydroindolone-
derived carbamates as Kv1.5 blockers. Bioorg Med Chem Lett 16:5855-5858
48. Gross MF, Beaudoin S, McNaughton-Smith G et al (2007) Aryl sulfonamido indane
inhibitors of the Kv1.5 ion channel. Bioorg Med Chem Lett 17:2849-2853
49. Beaudoin S, Reed AD, Gross M (2002) Preparation of N-indanyl sulfonamides as potassium
channel inhibitors, WO 2002060874, Icagen Incorporated, USA, p 72
50. Gross M, Beaudoin S, Reed AD (2001) Preparation of N-heterocyclylmethyl indanediamines
as potassium channel inhibitors, WO 2001046155, Icagen, Inc., USA, p 97
51. Beaudoin S, Gross MF, Reed AD et al (2002) Preparation of N-[(phenylsulfonylamino)
tetrahydronaphthyl]cyclopropanecarboxamides as potassium channel inhibitors for treat-
ment of cardiac arrhythmias, WO 2002008183, Icagen, Inc., USA, p 91
52. Reed AD, Gross MF, Beaudoin S (2002) Preparation of N-[(phenylsulfonylamino)
tetrahydronaphthyl]-3-phenylbutanamides as potassium channel inhibitors for treatment of
cardiac arrhythmias, WO 2002008191, Icagen, Inc., USA, p 98
53. Lloyd J, Atwal KS, Finlay HJ et al (2007) Benzopyran sulfonamides as Kv1.5 potassium
channel blockers. Bioorg Med Chem Lett 17:3271-3275
54. Matsuda T, Masumiya H, Tanaka N et al (2001) Inhibition by a novel anti-arrhythmic agent,
NIP-142, of cloned human cardiac K+ channel Kv1.5 current. Life Sci 68:2017-2024
